Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) Interest Expenses (2020 - 2025)

Barinthus Biotherapeutics' Interest Expenses history spans 6 years, with the latest figure at $13000.0 for Q4 2025.

  • For Q4 2025, Interest Expenses rose 8.33% year-over-year to $13000.0; the TTM value through Dec 2025 reached $51000.0, down 3.77%, while the annual FY2025 figure was $51000.0, 3.77% down from the prior year.
  • Interest Expenses reached $13000.0 in Q4 2025 per BRNS's latest filing, roughly flat from $13000.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $2.6 million in Q1 2021 to a low of $7000.0 in Q3 2023.
  • Average Interest Expenses over 5 years is $205285.7, with a median of $13000.0 recorded in 2025.
  • Peak YoY movement for Interest Expenses: crashed 99.32% in 2021, then surged 142.86% in 2024.
  • A 5-year view of Interest Expenses shows it stood at $18000.0 in 2021, then soared by 311.11% to $74000.0 in 2022, then tumbled by 90.54% to $7000.0 in 2023, then surged by 71.43% to $12000.0 in 2024, then increased by 8.33% to $13000.0 in 2025.
  • Per Business Quant, the three most recent readings for BRNS's Interest Expenses are $13000.0 (Q4 2025), $13000.0 (Q3 2025), and $12000.0 (Q2 2025).